A peer-reviewed study published in JACC: Advances has demonstrated that a risk prediction algorithm incorporating HeartBeam Inc.'s (NASDAQ: BEAT) portable ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%.
HeartBeam, a medical technology company focused on transforming cardiac care, stated that these results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program. The company's credit card-sized device is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG. This platform technology aims to deliver actionable heart intelligence for use outside medical facilities.
The study's findings are significant because they suggest that a portable, patient-friendly device could help triage chest pain patients more effectively, potentially reducing unnecessary hospital visits and improving outcomes for those at high risk of heart attack. The algorithm's high AUC, particularly when a baseline ECG is available, indicates strong diagnostic performance.
HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology. For more details on the intended use of its technology, refer to the company's Cleared Indications for Use.
The full press release is available at https://ibn.fm/ainxV. For the latest news and updates on BEAT, visit the company's newsroom at https://ibn.fm/BEAT.
